Long-term clinical outcomes after upgrade to resynchronization therapy: A propensity score–matched analysis
Mariana Brandão, MD, MSc, João Gonçalves Almeida, MD, MSc, Paulo Fonseca, MD, MSc and 8 more
Heart Rhythm O2 · 2021
doi:10.1016/j.hroo.2021.06.009 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background: Upgrade to cardiac resynchronization therapy (CRT) is common in Europe, despite little and conflicting evidence. Objective: To compare long-term clinical outcomes in a cohort of patients receiving de novo or upgrade to CRT. Methods: Single-center retrospective study of 295 consecutive patients submitted to CRT implantation between 2007 and 2018. Upgraded and de novo patients complying with a dedicated follow-up protocol were compared in terms of clinical (NYHA class improvement without major adverse cardiac events [MACE] in the first year of follow-up) and echocardiographic (left ventricle end-systolic volume reduction of >15% during the first year) response. Results: No differences in the rate of clinical (59.3% vs 62.6%, P =.765) or echocardiographic response (72.2% vs 71.9%, P =.970) between groups were observed. Device-related complications were also comparable between groups (8.9% vs 8.4%, P =.892). Occurrence of MACE and all-cause mortality were analyzed over a median follow-up of 3 (interquartile range 1–6) years: MACE occurred less frequently in the de novo group (hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.34–0.90, P =.018), but all-cause mortality was similar among groups (HR: 0.87, 95% CI: 0.46–1.64, P =.684). Propensity score–matching analysis was performed to adjust for possible confounder variables. In the propensity-matched samples, all-cause mortality (HR: 1.26, 95% CI: 0.56–2.77, P =.557) and MACE (HR: 0.84, 95% CI: 0.46–1.54, P =.574) were comparable between upgrade and de novo patients. Conclusion: Survival after upgrade to resynchronization therapy was comparable to de novo implants. Additionally, clinical and echocardiographic response to CRT in upgraded patients were similar to de novo patients.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.